# A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

> **NCT01740427** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 666 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** PD-0332991
- **DRUG:** Letrozole
- **DRUG:** Placebo
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT01740427
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-22
- **Primary completion:** 2016-02-26
- **Final completion:** 2023-11-09
- **Target enrollment:** 666 (ACTUAL)
- **Last updated:** 2024-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01740427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01740427, "A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01740427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*